Kuznicki Law, PLLC

Class Action Attorney

  • Current Cases
  • Attorneys
  • Practice Areas
  • Contact Us

Enovix Corporation (NasdaqGS: ENVX) Loss Submission Form

Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Northern District of California on behalf of shareholders of Enovix Corporation (“the Company”) f/k/a Rodgers Silicon Valley Acquisition Corp. (NasdaqGS: ENVX), if they purchased or otherwise acquired the Company’s shares between February 22, 2021 and January 3, 2023, inclusive (the “Class Period”), including shares of Rodgers Silicon prior to July 15, 2021.

Enovix and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 1, 2022, the Company announced its financial results for 3Q2022, disclosing just $8,000 in recognized revenue, that it would be “dialing back” efforts to improve existing manufacturing lines to focus on future manufacturing lines, and that it anticipated producing fewer than one million batteries in 2023. On this news, shares of Enovix plummeted approximately 44%.  Then, on January 3, 2023, the Company disclosed that its second production facility and future manufacturing lines would be delayed by several additional months due to equipment failures. On this news, shares of Enovix plummeted an additional 41%, further damaging investors.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until March 7, 2023 to request that the court appoint them lead plaintiff.

If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.

If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.

  • Loss Submission Form

    Kuznicki Law PLLC does not share your information with others. There is no other or obligation for you to submit.
  • Are you a current or former employee of Enovix Corporation f/k/a Rodgers Silicon Valley Acquisition Corp.?
  • Your Loss
    Please describe the nature of your loss. Including the approximate number of shares you purchased and sold within the class period.
  • Are there any other details you would like to share with us?
  • This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.
  • This field is for validation purposes and should be left unchanged.

Current Cases

  • Securities Class Actions
  • Mergers and Acquisition Litigations
  • Investigations

 About Us

  • Practice Areas
  • Our Attorneys
  • Contact Us
  • Privacy Policy

KUZNICKI LAW PLLC

445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Phone: (347) 696-1134
Cell : (347) 690-0692
Fax : (347) 348-0967

© 2018–2023 Kuznicki Law, PLLC Class Action Attorney · All Rights Reserved

The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation.
This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship.
ATTORNEY ADVERTISING and Prior results do not guarantee a similar outcome.